peptides researchOral Peptide Supplements: What Survives Digestion (and What Doesn't)

In 2019, Kristin Skov and colleagues at Aarhus University ran a clean tracer study. They labeled collagen peptides with stable isotopes and dosed them orally in human volunteers. Within hours, they detected intact prolyl-hydroxyproline dipeptides in plasma — and traced incorporation into bone collagen over the following weeks. This was real, measurable oral peptide bioavailability with hard pharmacokinetic data, not vendor marketing.

The same year, the peptide supplement market hit roughly $40 billion globally, the majority of it driven by claims about oral BPC-157, oral GHRP, oral CJC-1295, and a long list of "research peptides" sold as oral capsules. The pharmacokinetic literature supporting most of those claims is functionally absent. The gap between what the science demonstrates and what the market sells is one of the widest in modern supplementation.

The Gut Is a Peptide Furnace#

Peptides ingested orally face a sequence of biological barriers that most don't survive.

First, gastric acid. The stomach maintains a pH of 1.5–3.5, denaturing the three-dimensional structure of most peptides and unfolding them for proteolytic attack. Pepsin — the stomach's main protease — cleaves peptide bonds preferentially at aromatic and hydrophobic residues. By the time gastric contents reach the duodenum, longer peptides have already been substantially fragmented.

Second, pancreatic proteases. Trypsin, chymotrypsin, elastase, and carboxypeptidases are released into the small intestine and complete the work of breaking peptides down to amino acids and very short oligopeptides (di- and tripeptides, typically). These enzymes are abundant, specific, and efficient.

Third, brush border enzymes. The microvilli of small intestinal enterocytes carry surface-bound aminopeptidases, dipeptidyl peptidases (including DPP-4, the enzyme that degrades endogenous GLP-1), and a final layer of proteases. Any peptide that reaches this surface intact is subject to one more round of degradation.

Fourth, the absorption mechanism itself. Free amino acids cross the enterocyte via sodium-coupled transporters. Dipeptides and tripeptides cross via the PEPT1 transporter — a remarkably promiscuous carrier that accepts most short peptides regardless of sequence. Beyond three amino acids, transport across the intact intestinal epithelium drops sharply. Some longer peptides cross via paracellular pathways or transcytosis, but the efficiency is typically below 1–2% intact.

This is why injectable semaglutide costs what it does. The drug had to be engineered with an albumin-binding side chain to extend its half-life, and even then oral semaglutide (Rybelsus) required co-formulation with SNAC (sodium N-(8-(2-hydroxybenzoyl)amino) caprylate) — a specialized absorption enhancer that temporarily disrupts the gut epithelium — to achieve ~1% bioavailability. The engineering investment to make a 31-amino-acid peptide modestly orally bioavailable was substantial. Most consumer "oral peptide" products have done none of this engineering.

What Actually Survives#

A short list of peptide and peptide-like molecules have demonstrable oral bioavailability and clinical effects.

Hydrolyzed collagen peptides survive because they're already broken down to short fragments before ingestion. Manufacturers enzymatically hydrolyze collagen to molecular weights of 2–5 kDa, which corresponds to oligopeptides of 10–50 amino acids. These are further cleaved during digestion to dipeptides and tripeptides, some of which absorb intact via PEPT1. The Skov 2019 study is the clearest demonstration — prolyl-hydroxyproline (Pro-Hyp) dipeptides reached plasma in measurable concentrations and were subsequently incorporated into newly synthesized collagen.

The clinical effects are modest but real. Clark and colleagues (2008) showed 10 g/day of hydrolyzed collagen reduced activity-related joint pain in athletes over 24 weeks. Proksch and colleagues (2014) demonstrated improvements in skin elasticity. The mechanism is partially nutritional (delivering amino acids the body uses for endogenous collagen synthesis) and partially signaling (the Pro-Hyp dipeptide appears to stimulate fibroblast chemotaxis and proliferation).

Bone broth and gelatin deliver the amino acids but not the bioactive dipeptides — the hydrolysis step matters. Cost-effectively, generic hydrolyzed collagen powder at 10 g/day produces the documented effects; specialized "collagen peptide" products with proprietary blends rarely outperform.

Lactotripeptides (Ile-Pro-Pro and Val-Pro-Pro) are derived from milk casein, traditionally produced by Lactobacillus helveticus fermentation. They inhibit angiotensin-converting enzyme (ACE) — the same target as lisinopril and similar antihypertensives. Cicero's 2013 meta-analysis of 18 trials showed lactotripeptide supplementation reduced systolic blood pressure by approximately 5 mmHg and diastolic by 2 mmHg in hypertensive subjects.

The effect is modest compared to pharmaceutical ACE inhibitors (which typically drop systolic by 10–15 mmHg) but clinically meaningful. The tripeptides survive digestion partly because of their proline residues — proline-containing peptides resist many proteases — and absorb via PEPT1. Dosing in trials has ranged from 3–15 mg/day of the active tripeptides.

Bioactive milk peptides more broadly — beyond IPP and VPP — include casein-derived opioid peptides (casomorphins), immunomodulatory peptides, and antimicrobial peptides. The human evidence is most robust for the antihypertensive lactotripeptides.

Carnosine (beta-alanyl-histidine) is a dipeptide present in skeletal muscle and brain. Oral carnosine is hydrolyzed by serum carnosinase before reaching tissues, so direct supplementation has limited bioavailability. Beta-alanine — the rate-limiting precursor — is the more effective oral strategy and elevates muscle carnosine over 4–8 weeks of dosing. This is one of the few cases where the amino acid precursor outperforms the intact dipeptide.

L-glutamine is technically an amino acid, not a peptide, but it's worth mentioning because it absorbs reliably orally and is one of the few intestinal-targeted supplements with rigorous evidence. Doses of 5–10 g/day support gut barrier function in conditions of intestinal stress.

Soy and milk peptide fractions beyond IPP/VPP have been studied for additional cardiovascular and immune effects. Lactoferrin-derived peptides have antimicrobial and iron-binding properties; trials in elderly subjects have shown modest reductions in respiratory infection frequency with daily lactoferrin supplementation. Casein-derived antimicrobial peptides (isracidin) act locally in the gut against pathogenic bacteria. The evidence base for each is smaller than for collagen or lactotripeptides, but the mechanism — local effects in the gut rather than requiring systemic absorption — keeps the pharmacokinetic bar low and the safety profile clean.

BPC-157: The Overstated Case#

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a fragment of a human gastric juice protein. It has been studied extensively in rodent models by Predrag Sikiric's group in Zagreb, with reported effects on wound healing, gastric ulcer protection, tendon healing, and neuroprotection.

The animal evidence is genuine but the human translation is unclear. The published BPC-157 literature consists overwhelmingly of rodent studies. Human clinical trials are essentially absent — there are no FDA-approved indications, no published phase 1 pharmacokinetic studies establishing oral bioavailability in humans, and no peer-reviewed efficacy trials in human subjects.

What the rodent data does suggest is that BPC-157 has some local activity in the gut after oral dosing — the gastric ulcer protection effects are documented after oral administration in rats. Whether this translates to systemic effects in humans at consumer doses is speculative. Sikiric and colleagues' 2016 review in Current Neuropharmacology summarizes the brain-gut axis hypothesis but does not include human pharmacokinetic data.

The honest framing for consumers: oral BPC-157 may have local intestinal effects with some plausibility from animal data. Systemic effects from oral dosing — joint healing, tendon repair, anti-inflammatory effects throughout the body — are not supported by human pharmacokinetic studies. Injectable BPC-157 has stronger but still preliminary case-series evidence; oral BPC-157 sits at the speculative end of the spectrum.

The market sells the opposite framing. Most product descriptions promise systemic anti-inflammatory and regenerative effects from oral capsules. The peer-reviewed evidence does not support this claim at the level the marketing implies.

GHRP, CJC-1295, Ipamorelin: The Oral Mythology#

Growth hormone-releasing peptides (GHRP-2, GHRP-6, hexarelin, ipamorelin) and the GHRH analogue CJC-1295 are sold widely as oral supplements. The pharmacokinetic reality is that none of these survive oral dosing in any meaningful fraction.

These peptides are 5–30 amino acids long, contain standard L-amino acids, and lack any structural features that would resist gastric or pancreatic digestion. The injectable forms have established pharmacokinetics — peak plasma concentrations within 30 minutes, half-lives ranging from minutes (GHRP) to hours (CJC-1295 with DAC). Oral dosing produces no detectable plasma elevation in any rigorous study.

The mucosal sprays and sublingual formulations marketed for these peptides face the same problem at lower magnitude — the oral cavity has limited absorption surface area for peptides above 500 Da, and most of the product is swallowed and degraded. Bioavailability for sublingual peptides in this size range is typically below 1%.

The men who report subjective benefits from oral GHRP products are likely experiencing placebo, the effect of the cellulose and other excipients, or — in poorly regulated markets — actual injection-grade peptide that has been misformulated as oral. The evidence-based position is that this category does not work as marketed.

The same applies to oral thymosin alpha-1, oral PT-141, oral TB-500, and the broader catalog of research peptides repackaged for consumer supplement sale. None of these have published human oral pharmacokinetic data demonstrating systemic bioavailability. The injectable forms have varying degrees of evidence; the oral capsule forms have essentially none. The market exists because the FDA classification of peptides is complex and enforcement is selective, not because the bioavailability claims are valid.